Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 9 METERS BIOPHARMA, INC.NMTR · Entity 114271 | Director | July 06, 2020 | July 08, 2020 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 13, 2026 |
| Canton Strategic Holdings, Inc.HILS · Entity 6394 | 10% owner | January 11, 2022 | January 12, 2022 |
| Instil Bio, Inc.TIL · Entity 7177 | CFO and CBO | September 10, 2025 | September 12, 2025 |
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | Director | May 14, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
9 METERS BIOPHARMA, INC.
Report date July 06, 2020 · Filed July 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2030-07-06 | Direct | 150,000 |
Reported balance
After 2020-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-06 · Grant · Acquired 150,000 · Balance 150,000 F1: The option shall vest in 36 equal monthly installments beginning July 6, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in 36 equal monthly installments beginning July 6, 2020.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Canton Strategic Holdings, Inc.
Report date January 11, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectSee Footnote | 636,008 |
Reported balance
Holding disclosure · report date 2022-01-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 636,008 F1: Sandeep Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities held by such entity. |
| Convertible NoteSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-01-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: On May 10, 2021, the Registrant issued the Reporting Person a $60,000 note which matures on the earlier of (i) May 10, 2024 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing and shall be equal to the quotient obtained by dividing the outstanding amount of the note by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents. |
| Convertible NoteSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-01-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: On August 4, 2021, the Registrant issued the Reporting Person a Subordinated Convertible Promissory Note (the "August Note") in the principal amount of $40,000. The August Note matures upon the earlier of (i) August 4, 2024 and (ii) the closing of the Next Equity Financing. The principal amount of the August Note together with accrued interest thereon shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. The number of Equity Securities to be issued upon conversion of the August Note shall be equal to the quotient obtained by dividing the outstanding principal amount of the August Note together with interest accrued thereon by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. |
Filing footnotes · ownership attribution and instrument terms
F1: Sandeep Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities held by such entity.
F2: On May 10, 2021, the Registrant issued the Reporting Person a $60,000 note which matures on the earlier of (i) May 10, 2024 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing and shall be equal to the quotient obtained by dividing the outstanding amount of the note by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents.
F3: On August 4, 2021, the Registrant issued the Reporting Person a Subordinated Convertible Promissory Note (the "August Note") in the principal amount of $40,000. The August Note matures upon the earlier of (i) August 4, 2024 and (ii) the closing of the Next Equity Financing. The principal amount of the August Note together with accrued interest thereon shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. The number of Equity Securities to be issued upon conversion of the August Note shall be equal to the quotient obtained by dividing the outstanding principal amount of the August Note together with interest accrued thereon by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million.
Instil Bio, Inc.
Report date September 10, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-09-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-09-10 · Exercise / conversion · Acquired 17,000 · Balance 17,000 Row 2 · 2025-09-10 · Exercise / conversion · Acquired 13,000 · Balance 30,000 Row 3 · 2025-09-10 · Sale · Disposed 17,539 · Balance 12,461 F1: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.70 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Row 4 · 2025-09-10 · Sale · Disposed 12,461 · Balance 0 F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.60 · Expires 2034-02-09 | Direct | 17,000 |
Reported balance
After 2025-09-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-10 · Exercise / conversion · Disposed 17,000 · Balance 17,000 F3: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on February 10, 2025 with the remainder vesting in substantially equal monthly tranches thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.68 · Expires 2033-01-07 | Direct | 30,000 |
Reported balance
After 2025-09-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-10 · Exercise / conversion · Disposed 13,000 · Balance 30,000 F4: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on January 8, 2024 with the remainder vesting in substantially equal monthly tranches thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.70 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
F3: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on February 10, 2025 with the remainder vesting in substantially equal monthly tranches thereafter.
F4: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on January 8, 2024 with the remainder vesting in substantially equal monthly tranches thereafter.
Unicycive Therapeutics, Inc.
Report date May 14, 2026 · Filed July 28, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 47,941 |
Reported balance
After 2026-05-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 47,941 · Balance 47,941 F1: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2018 Filed Aug 30, 2018 20:38 UTC Amendment | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 250 | $4.90 | $1,225.00 |
DisclosureSEC source: 0001551986-18-000025 · wf-form4a_153567588887099.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 F1 · shares: These shares were inadvertently omitted from the original Form 4. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:13 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Options · Derivative | 37,209 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001104659-18-017151 · a4.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,188 Underlying: Common Stock · 37,209 shares Expires 2028-03-12 F1 · derivative.exercise_date: The shares underlying this stock option vest as follows: one-third (12,403 shares) on each of 3/12/2019, 3/12/2020 and 3/12/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.